GlassScriptPhysician profile
Catherine Cepeda
NPI 1295231900
$1,048.28
in general payments reported to CMS, 2019-2025
18 companies · $237 in 2025
The $237 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $174 · 2023: $379 · 2024: $258 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $874.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $257.05 | 2022-2025 | |
| Pfizer INC. | $74.01 | 2022-2024 | |
| Coopersurgical, INC. | $72.22 | 2023-2024 | Paragard T 380a, Paragard T 380a |
| Smith+Nephew, INC. | $67.56 | 2024-2025 | Pico 14 |
| Hologic Sales and Service, LLC | $67.36 | 2022-2023 | Aptima, Affirm Prone Biopsy System |
| Exeltis, USA INC. | $65.22 | 2023-2025 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $65.00 | 2023 | |
| Astellas Pharma US INC | $58.71 | 2025 | Veozah |
| Abbvie INC. | $50.16 | 2022-2023 | Orilissa |
| Sumitomo Pharma America, INC. | $48.79 | 2023-2024 | Myfembree |
| Solventum Corporation | $47.42 | 2024-2025 | Prevena, V.A.C. Veraflo Cleanse Choice |
| Agile Therapeutics, INC. | $37.79 | 2022-2023 | Twirla |
| Biogen, INC. | $34.97 | 2025 | Zurzuvae |
| Gynesonics, INC. | $30.91 | 2022 | |
| Millicent US INC | $23.22 | 2025 | Intrarosa, Femlyv |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $16.47 | 2024 | |
| Amgen INC. | $16.04 | 2025 | Evenity, Prolia |
| Myovant Sciences INC. | $15.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Cepeda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.